NASDAQ:CRON Cronos Group (CRON) Stock Price, News & Analysis $2.74 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.72 -0.02 (-0.55%) As of 05/22/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cronos Group Stock (NASDAQ:CRON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cronos Group alerts:Sign Up Key Stats Today's Range$2.70▼$2.7550-Day Range$2.39▼$2.8052-Week Range$1.84▼$3.43Volume766,797 shsAverage Volume1.54 million shsMarket Capitalization$1.03 billionP/E Ratio274.27Dividend YieldN/APrice Target$2.30Consensus RatingHold Company Overview Cronos Group Inc. is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands. The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings. Cronos Group also collaborates with research partners to explore novel formats such as edibles, softgel capsules and vaporization devices, leveraging in-house extraction technologies and proprietary formulations. Founded in 2012, Cronos Group has expanded its footprint beyond Canada through export agreements and strategic partnerships in key international markets, including Israel, Germany and Australia. In December 2018, the company entered a landmark strategic investment with Altria Group, which acquired a 45% equity stake to accelerate Cronos Group’s global expansion and product innovation efforts. Cronos Group also formed Cronos Fermentation, a joint venture with Ginkgo Bioworks, to explore fermentation-based production of rare cannabinoids at scale. Under the leadership of CEO Michael Gorenstein and a senior management team with deep expertise in consumer packaged goods, biotechnology and regulatory affairs, Cronos Group continues to prioritize research and development, operational excellence and responsible growth. The company’s strategic focus remains on advancing scientific innovation, broadening its product portfolio and expanding its presence in regulated markets worldwide.AI Generated. May Contain Errors. Read More Cronos Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreCRON MarketRank™: Cronos Group scored higher than 28% of companies evaluated by MarketBeat, and ranked 755th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingHold Consensus RatingCronos Group has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.Downside RiskCronos Group has a consensus price target of $2.30, representing about 16.1% downside from its current price of $2.74.Amount of Analyst CoverageCronos Group has only been the subject of 2 research reports in the past 90 days.Read more about Cronos Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cronos Group is 274.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Cronos Group is 274.27, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.01.Price to Book Value per Share RatioCronos Group has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cronos Group's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.28% of the float of Cronos Group has been sold short.Short Interest Ratio / Days to CoverCronos Group has a short interest ratio ("days to cover") of 1.59, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cronos Group has recently decreased by 2.59%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCronos Group does not currently pay a dividend.Dividend GrowthCronos Group does not have a long track record of dividend growth. News and Social Media2.7 / 5News SentimentN/A News SentimentCronos Group has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cronos Group this week, compared to 3 articles on an average week.Search Interest8 people have searched for CRON on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows9 people have added Cronos Group to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cronos Group insiders have not sold or bought any company stock.Percentage Held by Insiders7.80% of the stock of Cronos Group is held by insiders.Percentage Held by Institutions8.71% of the stock of Cronos Group is held by institutions.Read more about Cronos Group's insider trading history. Receive CRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cronos Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRON Stock News HeadlinesWeekly Roundup on the Cannabis Sector & Psychedelic SectorMay 18, 2026 | finance.yahoo.comCronos Expands Spinach STIX Pre Rolls And Chases Canadian Market ShareMay 18, 2026 | finance.yahoo.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.May 25 at 1:00 AM | Behind the Markets (Ad)Contrasting Cronos Group (NASDAQ:CRON) & Jaguar Animal Health (NASDAQ:JAGX)May 18, 2026 | americanbankingnews.comCronos Group Inc. (NASDAQ:CRON) Given Consensus Recommendation of "Hold" by BrokeragesMay 17, 2026 | americanbankingnews.comCronos Group (NASDAQ:CRON) Raised to "Buy" at Wall Street ZenMay 16, 2026 | americanbankingnews.comCronos Group IncMay 14, 2026 | edition.cnn.comCronos: Strong Q1 Earnings Driven By International Cannabis SalesMay 14, 2026 | seekingalpha.comSee More Headlines CRON Stock Analysis - Frequently Asked Questions How have CRON shares performed this year? Cronos Group's stock was trading at $2.63 at the start of the year. Since then, CRON stock has increased by 4.2% and is now trading at $2.74. How were Cronos Group's earnings last quarter? Cronos Group Inc. (NASDAQ:CRON) posted its quarterly earnings data on Monday, May, 11th. The company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. The company earned $58.97 million during the quarter, compared to analyst estimates of $42.20 million. Cronos Group had a negative trailing twelve-month return on equity of 1.26% and a negative net margin of 1.14%. Read the conference call transcript. Who are Cronos Group's major shareholders? Top institutional shareholders of Cronos Group include Dimensional Fund Advisors LP (0.71%), Renaissance Technologies LLC (0.53%), Silver Oak Securities Incorporated (0.17%) and AdvisorShares Investments LLC (0.14%). View institutional ownership trends. How do I buy shares of Cronos Group? Shares of CRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cronos Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cronos Group investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/11/2026Today5/25/2026AGM 20266/18/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CRON's financial health is in the Green zone, according to TradeSmith. CRON has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRON CIK1656472 Webwww.thecronosgroup.com Phone(416) 504-0004FaxN/AEmployees450Year Founded2013Price Target and Rating Average Price Target for Cronos Group$2.30 High Price Target$2.30 Low Price Target$2.30 Potential Upside/Downside-16.1%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.01 Trailing P/E Ratio274.27 Forward P/E Ratio39.14 P/E GrowthN/ANet Income-$9.45 million Net Margins-1.14% Pretax Margin-3.92% Return on Equity-1.26% Return on Assets-1.20% Debt Debt-to-Equity RatioN/A Current Ratio21.87 Quick Ratio20.73 Sales & Book Value Annual Sales$146.59 million Price / Sales7.03 Cash Flow$0.01 per share Price / Cash Flow218.55 Book Value$2.99 per share Price / Book0.92Miscellaneous Outstanding Shares376,270,000Free Float346,922,000Market Cap$1.03 billion OptionableOptionable Beta0.87 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CRON) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cronos Group Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cronos Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
